AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Schrodinger Stock Soars 13.79% on Promising Cancer Data
Generated by AI AgentAinvest Movers Radar
Friday, Apr 11, 2025 5:00 am ET1min read
Schrodinger's stock surged 13.79% in pre-market trading on April 11, 2025, driven by the company's recent announcements and developments.
Schrodinger, Inc. (SDGR) has unveiled promising preclinical data at the AACR 2025, highlighting the potential of its cancer inhibitors, SGR-3515 and SGR-4174. SGR-3515 has shown a promising therapeutic profile, while SGR-4174 is emerging as a potential game-changer in targeting KRAS-driven cancers, capturing significant attention in the oncology community.
Wall Street analysts have set an average one-year price target of $30.80 for
, indicating a potential 60.25% upside from the current price. This optimistic outlook is supported by the company's groundbreaking preclinical findings and the positive reception from the oncology community.Schrodinger's average recommendation from brokerage firms is 2.0, reflecting an "Outperform" status. This rating, along with the projected GF Value of $37.21, suggests a significant upside potential for the company's stock, driven by its innovative cancer treatments and promising preclinical data.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
ATRenew (RERE) Climbs 4.02% on Strong Q3 Results, Apple-Huawei Partnerships Boost Revenue 28.7%
Dec.18 2025
Compass (COMP) Rallies 1.99% Amid Antitrust Scrutiny Over $1.5B Acquisition
Dec.18 2025
Suzano (SUZ) Shares Surge 6.79% as 400% Capacity Expansion Targets Sustainable Absorbent Products Demand
Dec.18 2025
Iamgold (IAG) Rallies 2.15% in 3 Days on Share Buyback, Debt Reduction Amid Gold Sector Strength
Dec.18 2025
Village Farms International Stock Dives 6.46% Amid U.S. Cannabis Regulatory Uncertainties and Strategic Risks
Dec.18 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet